10x Genomics (TXG) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on 10x Genomics (TXG) is Neutral.

The composite score behind that read is +0.13, weighing +0.06 of bullish evidence against -0.13 bearish.

10x Genomics last closed at $80.65, +4.36% on the session.

Against the IVW growth benchmark the position is +3.56% over the forecast window.

The read is built from 15 underlying insights — 3 bullish and 12 bearish.

Agreement across those insights is 80%.

10x Genomics has no graded predictions yet. We publish our accuracy across thousands of stocks in the open, misses included.

On the fundamentals StockMap ranks 10x Genomics in the 32nd percentile on return on equity, where 100 is best.

10x Genomics is classified under Health Care / Life Sciences Tools & Services, with a market capitalisation of $10.07B.

StockMap tracks 10x Genomics as the 17th largest of the 41 companies it covers in the Life Sciences Tools & Services industry, part of the Health Care sector.

Across that group the current two-week reads are 37 Neutral, 2 Moderate Outperform and 2 Moderate Underperform.

On that composite 10x Genomics ranks 10th of 41 in the group, against a group median of +0.06.